Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib

Oncologist

Volumn 15, Issue 1, 2010, Pages 85-92

  Vincenzi, Bruno ^a   Santini, Daniele ^a   Russo, Antonio ^b   Addeo, Raffaele ^c   Giuliani, Francesco ^d   Montella, Liliana ^c   Rizzo, Sergio ^b   Venditti, Olga ^a   Frezza, Anna Maria ^a   Caraglia, Michele ^e   Colucci, Giuseppe ^d   Del Prete, Salvatore ^c   Tonini, Giuseppe ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c SAN GIOVANNI DI DIO HOSPITAL   (Italy)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^e SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Hepatocellular carcinoma; Skin rash; Sorafenib

Indexed keywords

SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CONTROL; CANCER PATIENT; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HUMAN; INCIDENCE; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PREDICTOR VARIABLE; PRIORITY JOURNAL; RASH; RETROSPECTIVE STUDY; SKIN TOXICITY; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; DISEASE PROGRESSION; DRUG ERUPTIONS; EXANTHEMA; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PYRIDINES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 75649116842     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0143     Document Type: Article

References (30)

1. Wilhelm SM, Carter C, Tang L et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099 -7109.
2. Moreno-Aspitia A, Morton RF, Hillman DW et al. Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336. J Clin Oncol 2009;27:11-15.
3. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24: 4293-4300.
4. Chu D, Lacouture ME, Fillos T et al. Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis. Acta Oncol 2008;47: 176-186.
5. Beldner M, Jacobson M, Burges GE et al. Localized palmar-plantar epidermal hyperplasia: A previously undefined dermatologic toxicity to sorafenib. The Oncologist 2007;12:1178 -1182.
6. Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol 2005;6:491-500.
7. Lee MW, Seo CW, Kim SW et al. Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 2004;84:23-26.
8. Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457- 481.
9. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977;35:1-39.
10. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34 187-220.
11. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
12. Addeo R, Caraglia M, Del Prete S. Highlights of regional meeting of Italian Southern Oncological Group (GOIM): Focus on hepatocellular carcinoma: Biological and clinical background, therapeutic guide-lines and perspectives. 7 November 2008, Naples, Italy. Expert Opin Investig Drugs 2009; 18:373-378.
13. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693- 699.
14. Benson AB, Abrams TA, Ben-Josef E et al. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers, Version I. Fort Washington, PA: National Comprehensive Cancer Network, 2010:1-59.
15. Lopez PM, Villanueva A, Llovet JM. Systematic review: Evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006;23:1535-1547.
16. Lo CM, Ngan H, TsoWKet al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164 -1171.
17. Llovet JM, Real MI, Montaña X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002;359: 1734-1739.
18. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378 -390.
19. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma:A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
20. Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. Meta-Analysis Group In Cancer. J Clin Oncol 1998;16:3537-3541.
21. Escudier B, Eisen T, Stadler WM et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-134.
22. Strumberg D, Richly H, Hilger RA et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 2005;23:965-972.
23. Busam KJ, Capodieci P, Motzer R et al. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169 -1176.
24. Jacot W, Bessis D, Jorda E et al. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004;151:238 -241.
25. Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345.
26. Van Cutsem E, Lang I, D'haens G et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008;26(15 suppl):2.
27. Scartozzi M, Galizia E, Chiorrini S et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009;20:227-230.
28. Ravaud A, Sire M. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. Ann Oncol 2009;20:966 -967; author reply 967.
29. Wick A, Schafer N, Dörner N et al. Arterial hypertension and bevacizumab treatment in glioblastoma: No correlation with clinical outcome. J Neurooncol 2009 Aug 29 [Epub ahead of print].
30. Saltz L, Kies M, Abbruzzese JL et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies (abstract 817). ProcAmSoc Clin Oncol 2003; 22:204.